The abstract is read at the publisher; the summary is JClub's.
mAb V1WT_06 targets a highly conserved RBD site V epitope on WIV-1 Spike, enabling broad sarbecovirus neutralisation linked to evolutionarily constrained contact residues.
- Why it matters: Ongoing SARS-CoV-2 evolution and sarbecovirus spillover create a need for cross-reactive monoclonal antibodies and conserved neutralising epitopes to guide broadly protective vaccine design.
- What they did: The study mapped neutralising epitopes on WIV-1 Spike using three mAbs (XEC, JN.1, XFG), including V1WT_06 (heavy-chain mediated site V) and V1WT_41/VA14_26 (overlapping class 4 epitopes with different ACE2 competition).
- The result: Neutralisation by these mAbs is maintained when viral entry uses Japanese horseshoe bat and Halcyon horseshoe bat ACE2s, supporting therapeutic development and pan-betacoronavirus vaccine rationale.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.